First-in-class YEATS inhibitors that show promise for leukemia treatment

A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong (HKU), in collaboration with scientists from Tsinghua University in China, the Rockefeller University, and the University of Texas MD Anderson Cancer Center in the United States, has developed the first chemical inhibitors against a novel therapeutic target for treatment of acute myeloid leukemia (AML), a fast-growing cancer of bone marrow and blood cells. The findings were recently published in Nature Chemical Biology.

Read the whole article on Physorg

More from Physorg